Risk Factors for Cutaneous Immune-Related Adverse Events: A Systematic Scoping Review

A systematic scoping review summarizing risk factors for cutaneous immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. The review analyzed 50 studies encompassing 198,514 participants, with 12.5% experiencing at least one cutaneous adverse event. Author Zhenzhen Su published the review on figshare in 2026.

Use Cases

• Identifying high-risk patient profiles for cutaneous adverse events based on demographic factors like age and gender.
• Analyzing associations between specific treatment regimens (e.g., camrelizumab) and adverse event subtypes.
• Investigating biomarker correlations (e.g., eosinophil count, cytokine levels) with adverse event development.
• Validating reported risk factors (e.g., melanoma tumor type) for specific cutaneous adverse event subtypes.

Strengths

• Analysis is based on a substantial participant pool of 198,514 individuals.
• Systematic methodology following PRISMA-ScR guidelines, searching 10 databases.
• Identifies and categorizes 68 distinct risk factors across three primary domains.

Limitations

• The dataset is a 153.7 KB DOCX file, indicating a limited scope focused on review text rather than raw data.
• Row count and column-level documentation are absent; data structure must be inferred from the document.
• The review notes significant variability in the quality of reporting for risk factors in the included studies.

Provenance

Source

figshare

Collection Method

Systematic scoping review conducted in accordance with PRISMA-ScR guidelines, searching PubMed, Embase, Cochrane, Web of Science, ProQuest, CINAHL, CNKI, Wanfang Data, VIP, and SinoMed.

Time Range

Studies from database inception to December 31, 2023.

Freshness

Last updated 2026-04-16 05:18:57.

Geography

Studies published in English and Chinese; participant geography is not specified.